<DOC>
	<DOC>NCT00892749</DOC>
	<brief_summary>This is a multi-center, open-labeled, non-comparative study to examine the safety and efficacy of ASP1585 for long-term dosing in chronic kidney disease and hyperphosphatemia patients on hemodialysis.</brief_summary>
	<brief_title>Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>Chronic kidney disease patients on hemodialysis Hyperphosphatemia Written informed consent Patients with gastrointestinal surgery or enterectomy Severe cardiac disease patients Patients with severe constipation or diarrhea Patients with a complication of malignant tumors Patients with uncontrolled hypertension Patients treated with parathyroid intervention</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>hyperphosphatemia</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>CKD</keyword>
	<keyword>ASP1585</keyword>
</DOC>